{"transactions":[{"id":2115267,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Chief Discovery Officer"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2022-11-16T21:19:59.000Z","date":"2022-11-14","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Retention Employee Stock Option became exercisable in two equal annual installments, beginning on this date."}],"balance_after":0,"derivative":{"exercise_price":1.42,"exercise_date":"2014-01-01","expiration_date":"2023-01-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001127602-22-025761","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222025761/form4.xml","form_type":"4"}},{"id":2115266,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Chief Discovery Officer"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2022-11-16T21:19:59.000Z","date":"2022-11-14","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Annual Employee Option Grant became exercisable in four equal annual installments, beginning on this date."}],"balance_after":0,"derivative":{"exercise_price":1.42,"exercise_date":"2014-01-01","expiration_date":"2023-01-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001127602-22-025761","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222025761/form4.xml","form_type":"4"}},{"id":2115265,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Chief Discovery Officer"}}],"security":"Common Stock","published_at":"2022-11-16T21:19:59.000Z","date":"2022-11-14","kind":"sale","acquired":false,"shares":31515,"price":13.88,"value":437428.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $13.86 to $13.92. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":298541,"source":{"system":"sec-edgar","filing":"0001127602-22-025761","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222025761/form4.xml","form_type":"4"}},{"id":2115264,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Chief Discovery Officer"}}],"security":"Common Stock","published_at":"2022-11-16T21:19:59.000Z","date":"2022-11-14","kind":"exercise","acquired":true,"shares":50000,"price":1.42,"value":71000.0,"ownership":{"direct":true},"balance_after":330056,"source":{"system":"sec-edgar","filing":"0001127602-22-025761","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222025761/form4.xml","form_type":"4"}},{"id":2115263,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Chief Discovery Officer"}}],"security":"Common Stock","published_at":"2022-11-16T21:19:59.000Z","date":"2022-11-14","kind":"exercise","acquired":true,"shares":50000,"price":1.42,"value":71000.0,"ownership":{"direct":true},"balance_after":280056,"source":{"system":"sec-edgar","filing":"0001127602-22-025761","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222025761/form4.xml","form_type":"4"}},{"id":2342955,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Chief Discovery Officer"}}],"security":"Common Stock","published_at":"2022-03-09T21:24:11.000Z","date":"2022-03-07","kind":"sale","acquired":false,"shares":20000,"price":17.16,"value":343200.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $17.05 to $17.27. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":230056,"source":{"system":"sec-edgar","filing":"0001127602-22-008780","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222008780/form4.xml","form_type":"4"}},{"id":2470721,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Chief Discovery Officer"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2021-12-16T22:09:07.000Z","date":"2021-12-14","kind":"grant","acquired":true,"shares":164000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Annual Employee Option Grant becomes exercisable at the rate of 25% of each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":164000,"derivative":{"exercise_price":11.43,"exercise_date":"2022-12-14","expiration_date":"2031-12-14","underlying":"Common Stock","underlying_shares":164000},"source":{"system":"sec-edgar","filing":"0001127602-21-031134","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221031134/form4.xml","form_type":"4"}},{"id":2470720,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Chief Discovery Officer"}}],"security":"Common Stock","published_at":"2021-12-16T22:09:07.000Z","date":"2021-12-14","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":250056,"source":{"system":"sec-edgar","filing":"0001127602-21-031134","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221031134/form4.xml","form_type":"4"}},{"id":2479724,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Chief Discovery Officer"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2021-12-09T21:38:55.000Z","date":"2021-12-07","kind":"exercise","acquired":false,"shares":62000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":4.73,"exercise_date":"2013-03-01","expiration_date":"2022-03-01","underlying":"Common Stock","underlying_shares":62000},"source":{"system":"sec-edgar","filing":"0001127602-21-030610","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221030610/form4.xml","form_type":"4"}},{"id":2479723,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Chief Discovery Officer"}}],"security":"Common Stock","published_at":"2021-12-09T21:38:55.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":30100,"price":12.2,"value":367220.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $12.18 to $12.22. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":215056,"source":{"system":"sec-edgar","filing":"0001127602-21-030610","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221030610/form4.xml","form_type":"4"}},{"id":2479722,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Chief Discovery Officer"}}],"security":"Common Stock","published_at":"2021-12-09T21:38:55.000Z","date":"2021-12-07","kind":"exercise","acquired":true,"shares":62000,"price":4.73,"value":293260.0,"ownership":{"direct":true},"balance_after":245156,"source":{"system":"sec-edgar","filing":"0001127602-21-030610","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221030610/form4.xml","form_type":"4"}},{"id":2841225,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Senior VP - Drug Discovery"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-23T21:25:02.000Z","date":"2021-02-19","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":4.15,"exercise_date":"2012-03-01","expiration_date":"2021-03-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001127602-21-007295","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221007295/form4.xml","form_type":"4"}},{"id":2841224,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Senior VP - Drug Discovery"}}],"security":"Common Stock","published_at":"2021-02-23T21:25:02.000Z","date":"2021-02-19","kind":"tax_withholding","acquired":false,"shares":22431,"price":11.53,"value":258629.43,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Shares of Common Stock delivered to the Company to satisfy payment of exercise price and tax withholding in connection with stock option exercise."}],"balance_after":183156,"source":{"system":"sec-edgar","filing":"0001127602-21-007295","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221007295/form4.xml","form_type":"4"}},{"id":2841223,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Senior VP - Drug Discovery"}}],"security":"Common Stock","published_at":"2021-02-23T21:25:02.000Z","date":"2021-02-19","kind":"exercise","acquired":true,"shares":50000,"price":4.15,"value":207500.0,"ownership":{"direct":true},"balance_after":205587,"source":{"system":"sec-edgar","filing":"0001127602-21-007295","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221007295/form4.xml","form_type":"4"}},{"id":2941056,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Senior VP - Drug Discovery"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2020-12-17T21:30:00.000Z","date":"2020-12-15","kind":"grant","acquired":true,"shares":280000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Annual Employee Option Grant becomes exercisable at the rate of 25% of each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":280000,"derivative":{"exercise_price":8.31,"exercise_date":"2021-12-15","expiration_date":"2030-12-15","underlying":"Common Stock","underlying_shares":280000},"source":{"system":"sec-edgar","filing":"0001127602-20-031788","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760220031788/form4.xml","form_type":"4"}},{"id":2955697,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Senior VP - Drug Discovery"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2020-12-07T21:19:02.000Z","date":"2020-12-03","kind":"grant","acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On December 3, 2020, the U.S. Food and Drug Administration approved oral, once-daily ORLADEYO? (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema in adults and pediatric patients 12 years and older. As a result, one of the vesting criteria associated with the performance-based stock options awarded to the reporting person on August 8, 2013 has been met. Therefore, 25% of such performance-based stock options vested on December 3, 2020."}],"balance_after":17000,"derivative":{"exercise_price":5.45,"exercise_date":"2020-12-03","expiration_date":"2023-08-08","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001127602-20-030696","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760220030696/form4.xml","form_type":"4"}},{"id":3250617,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Senior VP - Drug Discovery"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2020-02-25T21:42:40.000Z","date":"2020-02-21","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On February 21, 2020, the company received payment for 20,000 doses of RAPIVAB? (peramivir injection) delivered to the U.S. Department of Health and Human Services under the company's procurement contract. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 20% of the performance-based stock options vested."}],"balance_after":18000,"derivative":{"exercise_price":11.13,"exercise_date":"2020-02-21","expiration_date":"2024-12-22","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001127602-20-007672","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760220007672/form4.xml","form_type":"4"}},{"id":3264774,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Senior VP - Drug Discovery"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2020-02-19T22:03:28.000Z","date":"2020-02-14","kind":"grant","acquired":true,"shares":31500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On February 18, 2019, BioCryst Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has accepted and filed its new drug application for the approval of oral, once daily berotralstat (BCX7353) for the prevention of hereditary angioedema attacks. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 35% of the performance-based stock options vested."}],"balance_after":31500,"derivative":{"exercise_price":11.13,"exercise_date":"2020-02-14","expiration_date":"2024-12-22","underlying":"Common Stock","underlying_shares":31500},"source":{"system":"sec-edgar","filing":"0001127602-20-006501","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760220006501/form4.xml","form_type":"4"}},{"id":3335651,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Senior VP - Drug Discovery"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2019-12-19T22:52:56.000Z","date":"2019-12-17","kind":"grant","acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":225000,"derivative":{"exercise_price":3.23,"exercise_date":"2020-12-17","expiration_date":"2029-12-17","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0001127602-19-035551","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219035551/form4.xml","form_type":"4"}},{"id":3369129,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Senior VP - Drug Discovery"}}],"security":"Common Stock","published_at":"2019-11-18T21:03:26.000Z","date":"2019-11-18","kind":"purchase","acquired":true,"shares":25000,"price":1.45,"value":36250.0,"ownership":{"direct":true},"balance_after":155587,"source":{"system":"sec-edgar","filing":"0001127602-19-033004","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219033004/form4.xml","form_type":"4"}},{"id":3678438,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Senior VP - Drug Discovery"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2019-02-04T21:13:08.000Z","date":"2019-01-31","kind":"exercise","acquired":false,"shares":12188,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":1.2,"exercise_date":"2010-03-02","expiration_date":"2019-03-02","underlying":"Common Stock","underlying_shares":12188},"source":{"system":"sec-edgar","filing":"0001127602-19-003737","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219003737/form4.xml","form_type":"4"}},{"id":3678437,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Senior VP - Drug Discovery"}}],"security":"Non-Qualified Stock Option","published_at":"2019-02-04T21:13:08.000Z","date":"2019-01-31","kind":"exercise","acquired":false,"shares":19686,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":1.2,"exercise_date":"2010-03-02","expiration_date":"2019-03-02","underlying":"Common Stock","underlying_shares":19686},"source":{"system":"sec-edgar","filing":"0001127602-19-003737","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219003737/form4.xml","form_type":"4"}},{"id":3678436,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Senior VP - Drug Discovery"}}],"security":"Common Stock","published_at":"2019-02-04T21:13:08.000Z","date":"2019-01-31","kind":"tax_withholding","acquired":false,"shares":1685,"price":8.68,"value":14625.8,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Shares of Common Stock delivered to the Company to satisfy payment of exercise price in connection with stock option exercise."}],"balance_after":130587,"source":{"system":"sec-edgar","filing":"0001127602-19-003737","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219003737/form4.xml","form_type":"4"}},{"id":3678435,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Senior VP - Drug Discovery"}}],"security":"Common Stock","published_at":"2019-02-04T21:13:08.000Z","date":"2019-01-31","kind":"exercise","acquired":true,"shares":12188,"price":1.2,"value":14625.6,"ownership":{"direct":true},"balance_after":132272,"source":{"system":"sec-edgar","filing":"0001127602-19-003737","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219003737/form4.xml","form_type":"4"}},{"id":3678434,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Senior VP - Drug Discovery"}}],"security":"Common Stock","published_at":"2019-02-04T21:13:08.000Z","date":"2019-01-31","kind":"tax_withholding","acquired":false,"shares":7702,"price":8.68,"value":66853.36,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Shares of Common Stock delivered to the Company to satisfy payment of exercise price and tax withholding in connection with stock option exercise."}],"balance_after":120084,"source":{"system":"sec-edgar","filing":"0001127602-19-003737","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219003737/form4.xml","form_type":"4"}},{"id":3678433,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Senior VP - Drug Discovery"}}],"security":"Common Stock","published_at":"2019-02-04T21:13:08.000Z","date":"2019-01-31","kind":"exercise","acquired":true,"shares":19686,"price":1.2,"value":23623.2,"ownership":{"direct":true},"balance_after":127786,"source":{"system":"sec-edgar","filing":"0001127602-19-003737","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219003737/form4.xml","form_type":"4"}},{"id":3710945,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Senior VP - Drug Discovery"}}],"security":"Common Stock","published_at":"2019-01-03T21:36:46.000Z","date":"2019-01-01","kind":"tax_withholding","acquired":false,"shares":771,"price":8.07,"value":6221.97,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2015."}],"balance_after":108100,"source":{"system":"sec-edgar","filing":"0001127602-19-000730","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219000730/form4.xml","form_type":"4"}},{"id":3722618,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Senior VP - Drug Discovery"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2018-12-21T21:10:57.000Z","date":"2018-12-20","kind":"grant","acquired":true,"shares":235000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":235000,"derivative":{"exercise_price":7.06,"exercise_date":"2019-12-20","expiration_date":"2028-12-20","underlying":"Common Stock","underlying_shares":235000},"source":{"system":"sec-edgar","filing":"0001127602-18-037173","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218037173/form4.xml","form_type":"4"}},{"id":4006655,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Senior VP - Drug Discovery"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2018-03-08T20:48:10.000Z","date":"2018-03-06","kind":"exercise","acquired":false,"shares":9378,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":3.26,"exercise_date":"2009-03-14","expiration_date":"2018-03-14","underlying":"Common Stock","underlying_shares":9378},"source":{"system":"sec-edgar","filing":"0001127602-18-010694","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218010694/form4.xml","form_type":"4"}},{"id":4006654,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Senior VP - Drug Discovery"}}],"security":"Non-Qualified Stock Option","published_at":"2018-03-08T20:48:10.000Z","date":"2018-03-06","kind":"exercise","acquired":false,"shares":20622,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":3.26,"exercise_date":"2009-03-14","expiration_date":"2018-03-14","underlying":"Common Stock","underlying_shares":20622},"source":{"system":"sec-edgar","filing":"0001127602-18-010694","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218010694/form4.xml","form_type":"4"}},{"id":4006653,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Senior VP - Drug Discovery"}}],"security":"Common Stock","published_at":"2018-03-08T20:48:10.000Z","date":"2018-03-06","kind":"tax_withholding","acquired":false,"shares":5902,"price":5.18,"value":30572.36,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Shares of Common Stock delivered to the Company to satisfy payment of exercise price in connection with stock option exercise."}],"balance_after":108871,"source":{"system":"sec-edgar","filing":"0001127602-18-010694","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218010694/form4.xml","form_type":"4"}},{"id":4006652,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Senior VP - Drug Discovery"}}],"security":"Common Stock","published_at":"2018-03-08T20:48:10.000Z","date":"2018-03-06","kind":"exercise","acquired":true,"shares":9378,"price":3.26,"value":30572.28,"ownership":{"direct":true},"balance_after":114773,"source":{"system":"sec-edgar","filing":"0001127602-18-010694","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218010694/form4.xml","form_type":"4"}},{"id":4006651,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Senior VP - Drug Discovery"}}],"security":"Common Stock","published_at":"2018-03-08T20:48:10.000Z","date":"2018-03-06","kind":"tax_withholding","acquired":false,"shares":15223,"price":5.18,"value":78855.14,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Shares of Common Stock delivered to the Company to satisfy payment of exercise price and tax withholding in connection with stock option exercise."}],"balance_after":105395,"source":{"system":"sec-edgar","filing":"0001127602-18-010694","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218010694/form4.xml","form_type":"4"}},{"id":4006650,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Senior VP - Drug Discovery"}}],"security":"Common Stock","published_at":"2018-03-08T20:48:10.000Z","date":"2018-03-06","kind":"exercise","acquired":true,"shares":20622,"price":3.26,"value":67227.72,"ownership":{"direct":true},"balance_after":120618,"source":{"system":"sec-edgar","filing":"0001127602-18-010694","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218010694/form4.xml","form_type":"4"}},{"id":4092902,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Senior VP - Drug Discovery"}}],"security":"Common Stock","published_at":"2018-01-23T14:10:34.000Z","date":"2018-01-20","kind":"tax_withholding","acquired":false,"shares":3872,"price":5.59,"value":21644.48,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2014."}],"balance_after":99996,"source":{"system":"sec-edgar","filing":"0001127602-18-002235","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218002235/form4.xml","form_type":"4"}},{"id":4114667,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Senior VP - Drug Discovery"}}],"security":"Common Stock","published_at":"2018-01-03T14:11:29.000Z","date":"2018-01-01","kind":"tax_withholding","acquired":false,"shares":838,"price":4.91,"value":4114.58,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2015."}],"balance_after":103868,"source":{"system":"sec-edgar","filing":"0001127602-18-000306","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218000306/form4.xml","form_type":"4"}},{"id":4122959,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Senior VP - Drug Discovery"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2017-12-22T15:13:05.000Z","date":"2017-12-20","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":100000,"derivative":{"exercise_price":5.04,"exercise_date":"2018-12-20","expiration_date":"2027-12-20","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001127602-17-035401","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760217035401/form4.xml","form_type":"4"}},{"id":4218735,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Senior VP - Drug Discovery"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2017-09-05T19:37:34.000Z","date":"2017-08-31","kind":"grant","acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 30, 2017, the Science Committee of the Board of Directors determined that the BCX7353 APeX-1 clinical trial met its goals and BCX7353 warrants further development. As a result, on August 31, 2017, the Compensation Committee of the Board of Directors determined that one of the vesting criteria associated with the performance-based stock options awarded in December 2014 to all employees, excluding the Chief Executive Officer, has been met. Therefore, 30% of the performance-based stock options vested on August 31, 2017."}],"balance_after":27000,"derivative":{"exercise_price":11.13,"exercise_date":"2017-08-31","expiration_date":"2024-12-22","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001127602-17-026938","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760217026938/form4.xml","form_type":"4"}},{"id":4415597,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Senior VP - Drug Discovery"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2017-03-01T18:50:52.000Z","date":"2017-02-27","kind":"grant","acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":175000,"derivative":{"exercise_price":5.51,"exercise_date":"2018-02-27","expiration_date":"2027-02-27","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001127602-17-009099","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760217009099/form4.xml","form_type":"4"}},{"id":4483410,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Senior VP - Drug Discovery"}}],"security":"Common Stock","published_at":"2017-01-24T14:25:16.000Z","date":"2017-01-20","kind":"tax_withholding","acquired":false,"shares":5083,"price":5.95,"value":30243.85,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's federal and state tax withholding obligations upon the vesting of restricted stock units granted in 2014."}],"balance_after":104706,"source":{"system":"sec-edgar","filing":"0001127602-17-002250","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760217002250/form4.xml","form_type":"4"}},{"id":4508844,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":122353,"kind":"person","name":"Babu Yarlagadda S","position":1,"cik":"0001452635","reported_name":"Babu Yarlagadda S","relationship":{"officer":true,"officer_title":"Senior VP - Drug Discovery"}}],"security":"Common Stock","published_at":"2017-01-03T19:09:44.000Z","date":"2017-01-01","kind":"tax_withholding","acquired":false,"shares":1639,"price":6.33,"value":10374.87,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2013 and 2015."}],"balance_after":109789,"source":{"system":"sec-edgar","filing":"0001127602-17-000077","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760217000077/form4.xml","form_type":"4"}}]}